Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX +/- cetusimab: NCCTG N0147.
- Citation:
- J Clin Oncol vol 30 (15_suppl) 3514-3514
- Meeting Instance:
- ASCO 2012
- Year:
- 2012
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2105
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Bristol-Myers Squibb, ImClone, Sanofi-Aventis, and Pfizer.
- Grants:
- NIH Grant CA 25224, NCI K05CA 142885
- Corr. Author:
- Authors:
- Frank A. Sinicrope Michelle R. Mahoney Thomas C. Smyrk Stephen N. Thibodeau Richard M. Goldberg Daniel J. Sargent Garth D. Nelson Steven R. Alberts
- Networks:
- Study
- NCCTG-N0147
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: